An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
CLBQ707A1101 assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients.
Advanced Solid Tumors
DRUG: Gimatecan
Safety and tolerability assessed by Adverse Events, 2.8 years|Anti-tumor activity assessed by RECIST criteria, 2.8 years
CLBQ707A1101 assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients.